Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, Beltrametti C, Damiani M, Andrioli G C, Pugliese R, Iorio A, Brambilla G
Istituto di Medicina Interna e Medicina Vascolare, Università di Perugia, Italy.
N Engl J Med. 1998 Jul 9;339(2):80-5. doi: 10.1056/NEJM199807093390204.
Compression stockings are recommended for prophylaxis against venous thromboembolism in patients undergoing neurosurgery, but anticoagulant agents have not gained wide acceptance because of concern about intracranial bleeding.
In a multicenter, randomized, double-blind trial, we assessed the efficacy and safety of enoxaparin in conjunction with the use of compression stockings in the prevention of venous thromboembolism in patients undergoing elective neurosurgery. Enoxaparin (40 mg once daily) or placebo was given subcutaneously for not less than seven days beginning within 24 hours after the completion of surgery. The primary end point was symptomatic, objectively confirmed venous thromboembolism or deep-vein thrombosis assessed by bilateral venography, which was performed in all patients on day 8+/-1. Bleeding side effects were carefully assessed.
Among the 307 patients assigned to treatment groups, 129 of the 154 patients receiving placebo (84 percent) and 130 of the 153 patients receiving enoxaparin (85 percent) had venographic studies adequate for analysis. An additional patient in the placebo group died before venography of autopsy-confirmed pulmonary embolism. In this analysis, 42 patients given placebo (32 percent) and 22 patients given enoxaparin (17 percent) had deep-vein thrombosis (relative risk in the enoxaparin group, 0.52; 95 percent confidence interval, 0.33 to 0.82; P=0.004). The rates of proximal deep-vein thrombosis were 13 percent in patients receiving placebo and 5 percent in patients receiving enoxaparin (relative risk in the enoxaparin group, 0.41; 95 percent confidence interval, 0.17 to 0.95; P=0.04). Two patients in the placebo group died of autopsy-confirmed pulmonary embolism on days 9 and 16. Major bleeding occurred in four patients receiving placebo (intracranial bleeding in all four) and four patients (intracranial bleeding in three) receiving enoxaparin (3 percent of each group).
Enoxaparin combined with compression stockings is more effective than compression stockings alone for the prevention of venous thromboembolism after elective neurosurgery and does not cause excessive bleeding.
对于接受神经外科手术的患者,推荐使用弹力袜预防静脉血栓栓塞,但由于担心颅内出血,抗凝剂尚未得到广泛应用。
在一项多中心、随机、双盲试验中,我们评估了依诺肝素联合弹力袜在择期神经外科手术患者预防静脉血栓栓塞中的疗效和安全性。手术结束后24小时内开始皮下注射依诺肝素(40mg每日一次)或安慰剂,持续不少于7天。主要终点是通过双侧静脉造影评估的有症状的、经客观证实的静脉血栓栓塞或深静脉血栓形成,所有患者在第8±1天进行此项检查。仔细评估出血副作用。
在分配到治疗组的307例患者中,154例接受安慰剂的患者中有129例(84%)以及153例接受依诺肝素的患者中有130例(85%)进行了适合分析的静脉造影检查。安慰剂组有1例患者在静脉造影前死于经尸检证实的肺栓塞。在此分析中,42例接受安慰剂的患者(32%)和22例接受依诺肝素的患者(17%)发生了深静脉血栓形成(依诺肝素组的相对风险为0.52;95%置信区间为0.33至0.82;P=0.004)。接受安慰剂的患者近端深静脉血栓形成率为13%,接受依诺肝素的患者为5%(依诺肝素组的相对风险为0.41;95%置信区间为0.17至0.95;P=0.04)。安慰剂组有2例患者分别在第9天和第16天死于经尸检证实的肺栓塞。4例接受安慰剂的患者(全部为颅内出血)和4例接受依诺肝素的患者(3例为颅内出血)发生了严重出血(每组3%)。
依诺肝素联合弹力袜在预防择期神经外科手术后静脉血栓栓塞方面比单独使用弹力袜更有效,且不会引起过多出血。